Drug Safety Needs Global Cooperation Of Drug Regulators, Officials Say 19/05/2012 by Catherine Saez, Intellectual Property Watch Leave a Comment On the eve of the World Health Assembly, the permanent mission of Brazil organised an informal meeting on sanitary regulation and how to improve cooperation among drug regulatory agencies. Major stakeholders were invited to present challenges and ongoing efforts to improve global quality, safety and efficacy of medical products.
DNDi Backs WHO ‘Neglected Patients’ R&D Treaty 11/05/2012 by Intellectual Property Watch Leave a Comment The Drugs for Neglected Diseases initiative (DNDi) has released a policy brief in support of the proposed R&D convention to be considered at the upcoming World Health Assembly.
New IFPMA-Backed Report On R&D For Diseases In Developing Countries 10/05/2012 by Intellectual Property Watch Leave a Comment With the launch of a new report concerning research and development for diseases predominately afflicting developing countries, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) today convened a panel of public health specialists to discuss the findings.
Draft Proposal Calls For Delay Of WHO R&D Treaty Talks 03/05/2012 by William New, Intellectual Property Watch 2 Comments A new draft proposal suggests that World Health Organization members postpone negotiations for a convention on financing of research and development for diseases predominantly afflicting poor populations. The negotiation of a convention is up for discussion by members at the annual World Health Assembly this month.
Full Agenda For WHO: Reform, R&D Convention, Substandard Medicines, NCDs, Pandemics 02/05/2012 by Rachel Marusak Hermann, Intellectual Property Watch Leave a Comment With just over two weeks until the annual UN World Health Assembly begins, member states face a substantive agenda, including a sweeping reform programme, an innovative public health proposal, the global strategy for the prevention and control of noncommunicable diseases, a mechanism to fight poor quality medicines, and progress in pandemic influenza preparedness.
Confidential Documents Show Tough Staff Choices At Global Fund 27/04/2012 by William New, Intellectual Property Watch Leave a Comment Once seen as a rising star on the global public health scene, the Geneva-based Global Fund to Fight AIDS, Tuberculosis and Malaria is in the throes of a top-down reform as it seeks to tailor its efforts to meet new realities, especially reductions in funding. While the new administration works to improve performance, a confidential document obtained by Intellectual Property Watch shows the terms on which departing staff is being asked to separate from the international organisation.
Book Offers Timely Insights On IP, Drugs And Public Health In Developing Countries 25/04/2012 by Intellectual Property Watch Leave a Comment A recent book comes in time for the international policy debates coming to a head over access to medicines, intellectual property rights and public health in developing countries.
Text Of Kenya Judgment On Anti-Counterfeiting Now Available 23/04/2012 by Intellectual Property Watch Leave a Comment A copy of a key judgment by the High Court of Kenya last week that found a national anti-counterfeiting law was overly broad and might interfere with access to generic medicines is now available on Intellectual Property Watch.
Kenyan High Court’s Overturning Of Anti-Counterfeit Law Hailed 21/04/2012 by Intellectual Property Watch 3 Comments The High Court of Kenya yesterday ruled that the country’s 2008 Anti-Counterfeit Act was too broad and could interfere with the flow of legal generic medicines to patients, leading the UNAIDS organisation to issue a statement praising the decision. It also said intellectual property rights are not more important than life and health, according to UNAIDS.
The WHO’s Final Sprint Toward An International Convention On R&D 20/04/2012 by Rachel Marusak Hermann, Intellectual Property Watch Leave a Comment An international convention on research and development for neglected diseases has never been so closely within reach. A World Health Organization expert group is recommending the implementation of a legally binding instrument to secure new sources of funding to spur health research in areas where the current system has failed.